Return to study ST002845 main page
MB Sample ID: SA308439
Local Sample ID: | ID_1 |
Subject ID: | SU002957 |
Subject Type: | Human |
Subject Species: | Homo sapiens |
Taxonomy ID: | 9606 |
Gender: | Male and female |
Species Group: | Mammals |
Select appropriate tab below to view additional metadata details:
Subject:
Subject ID: | SU002957 |
Subject Type: | Human |
Subject Species: | Homo sapiens |
Taxonomy ID: | 9606 |
Gender: | Male and female |
Species Group: | Mammals |
Factors:
Local Sample ID | MB Sample ID | Factor Level ID | Level Value | Factor Name |
---|---|---|---|---|
ID_1 | SA308439 | FL037126 | D14 | Time-point |
ID_1 | SA308439 | FL037126 | MP | Treatment |
ID_1 | SA308439 | FL037126 | M | Sex |
Collection:
Collection ID: | CO002950 |
Collection Summary: | The COVID-19 infected participants in this study were drawn from the MetCOVID study, a parallel, double blind, randomized, placebo-controlled Phase IIb clinical trial, that assessed the efficacy of MP in treating hospitalized patients with suspected SARS-CoV-2 infection. Individuals with COVID-19 were admitted at the Hospital e Pronto-Socorro Delphina Rinaldi Abdel Aziz, in Manaus, Western Brazilian Amazon. The hospital was the largest public reference unit for the treatment of severe COVID-19 cases in the city. After confirmation of SARS-CoV-2 infection by RT-qPCR testing of nasopharyngeal swabs, blood was collected from patients and the separated plasma was stored at -80oC. The plasma samples were collected at the day of inclusion (D1) before treatment, and day five (D5), day seven (D7), day eleven (D11), and day fourteen (D14) after the start of treatment for metabolomic analysis. |
Sample Type: | Blood (plasma) |
Treatment:
Treatment ID: | TR002966 |
Treatment Summary: | The participants were administered with either intravenous sodium succinate MP (0.5 mg/kg) or placebo (saline solution) twice daily for 5 days. As per hospital protocol, all patients meeting acute respiratory distress syndrome criteria also preemptively received intravenous ceftriaxone (1g twice daily for 7 days) plus azithromycin (500 mg once a day for 5 days) or clarithromycin (500 mg twice daily for 7 days), starting on Day 1. At inclusion, adult patients were excluded if they had a history of hypersensitivity to MP, were living with human immunodeficiency virus or AIDS, had a history of chronic use of corticosteroids or immunosuppressive agents, were pregnant or breastfeeding, or had decompensated cirrhosis or chronic renal failure. |
Sample Preparation:
Sampleprep ID: | SP002963 |
Sampleprep Summary: | Metabolites were extracted from plasma samples using acetonitrile (2:1, v/v). Stable isotopes caffeine-¹³C3 and progesterone-d9 were used as internal standards. |
Combined analysis:
Analysis ID | AN004663 |
---|---|
Analysis type | MS |
Chromatography type | Reversed phase |
Chromatography system | Agilent 1220 Infinity |
Column | Agilent Zorbax Eclipse Plus C18 (150 x 4.6mm,3.5um) |
MS Type | ESI |
MS instrument type | Orbitrap |
MS instrument name | Thermo Q Exactive Orbitrap |
Ion Mode | POSITIVE |
Units | intesity |
Chromatography:
Chromatography ID: | CH003509 |
Chromatography Summary: | The binary mobile phases were water 0.5% formic acid with 5 mM of ammonium formate (A), and acetonitrile (B). Their gradient elution started with 20% (B) for 5 min, then linearly increased to 100% (B) in 30 min and kept constant for 8 min in 100% (B). The eluent was restored to the initial conditions in 4 minutes to re-equilibrate the column and held for the remaining 8 minutes. The flow rate was kept at 0.5 mL min-1. The injection volume for analysis was 3 μL, and the column temperature was set at 35 °C. |
Instrument Name: | Agilent 1220 Infinity |
Column Name: | Agilent Zorbax Eclipse Plus C18 (150 x 4.6mm,3.5um) |
Column Temperature: | 35 |
Flow Gradient: | gradient elution started with 20% (B) for 5 min, then linearly increased to 100% (B) in 30 min and kept constant for 8 min in 100% (B). The eluent was restored to the initial conditions in 4 minutes to re-equilibrate the column and held for the remaining 8 minutes. |
Flow Rate: | 0.5 mL/min |
Solvent A: | 100% water; 0.5% formic acid; 5 mM of ammonium formate |
Solvent B: | 100% acetonitrile |
Chromatography Type: | Reversed phase |
MS:
MS ID: | MS004410 |
Analysis ID: | AN004663 |
Instrument Name: | Thermo Q Exactive Orbitrap |
Instrument Type: | Orbitrap |
MS Type: | ESI |
MS Comments: | The electrospray ionization was operating with the following settings: spray voltage 3.5 kV; capillary temperature: 269 °C; S-lens RF level 50 V; sheath gas flow rate at 53 L min-1; aux gas flow rate at 14 L min-1; sweep gas flow rate 3 L min-1. The high-resolution mass-spectrometry was obtained under full MS/dd-MS2 mode. The mass range in the full MS scanning experiments was m/z 80-1200. The max IT was set at 200 ms, and AGC target was set at 1 x 106. For fragmentation acquisition, the top 5 (TopN, 5, loop count 5) most abundant precursors were sequentially transferred into the C-Trap (AGC target 1 x 105; max IT 50 ms) for collision. The collision energy for target analytes was 20, 30 and 35 eV. Resolving power was set at 140,000 and 70,000 for full MS and dd-MS2 acquisitions, respectively. |
Ion Mode: | POSITIVE |